John F. Crowley, the biotech visionary and current president and CEO of the Biotechnology Innovation Organization (BIO), will address the Emily Whitehead Foundation’s 2026 Believe Ball on Friday, September 25, 2026, at The Crystal Tea Room in Philadelphia’s historic Wanamaker Building. The keynote appearance connects one of biotechnology’s most compelling personal stories to an event dedicated to advancing breakthrough therapies that save lives—a convergence that underscores why Philadelphia has become a epicenter for rare disease and cancer treatment innovation. With over 400 guests expected to attend, including patients, caregivers, scientists, and industry leaders, Crowley’s address will bring together the human stakes of medical discovery with the business and scientific realities of scaling life-saving treatments globally.
Crowley’s presence at the Believe Ball is far more than a standard corporate speaking engagement. His story—from desperate father seeking a cure for his dying children to pharmaceutical entrepreneur whose company changed the course of neuromuscular disease treatment—has already inspired a major motion picture and reshaped how the biotech industry thinks about patient-driven innovation. His appearance in Philadelphia carries particular weight because the city is home to Emily Whitehead, the first child in the world to be saved by CAR T-cell therapy, a revolutionary immunotherapy approach that has since become one of the most promising tools against certain blood cancers. The Believe Ball serves a specific purpose: to create meaningful dialogue between people fighting for survival and the industry leaders with the power to scale advanced therapies worldwide. For attendees—many of whom have faced devastating diagnoses or watched loved ones struggle with rare or advanced diseases—Crowley’s keynote represents more than inspiration; it represents proof that transformative medical breakthroughs can happen, and that the path from desperation to cure, though extraordinarily difficult, is achievable.
Table of Contents
- What Drove John Crowley to Become a Biotech Leader?
- The Emily Whitehead Foundation’s Mission and Philadelphia’s Medical Legacy
- How Crowley’s Personal Journey Informs His Leadership at BIO
- Why the Believe Ball Matters to Industry Leaders and the Broader Biotech Community
- CAR T-Cell Therapy and the Challenge of Bringing Innovation to Scale
- The Role of Rare Disease Advocacy in Accelerating Breakthrough Treatments
- The September 25, 2026 Gathering and What It Represents
What Drove John Crowley to Become a Biotech Leader?
john Crowley’s path to becoming president and CEO of the Biotechnology Innovation Organization began with a crisis that most parents cannot fathom. In 1998, two of his children received a diagnosis that many considered a death sentence: Pompe disease, a rare neuromuscular disorder that progressively weakens muscles and, in infantile-onset cases, typically proves fatal within the first few years of life. Rather than accept this outcome, Crowley made a decision that would reshape his life and, ultimately, contribute to the trajectory of biotechnology innovation. He co-founded Novazyme Pharmaceuticals with the explicit goal of developing an experimental treatment that could save his children’s lives. This story of personal tragedy transformed into pharmaceutical action became the subject of the 2015 film *Extraordinary Measures*, which dramatized the race to develop an enzyme replacement therapy for Pompe disease.
The film captured not only the scientific challenge but also the emotional weight of fighting against time and medical convention to save one’s own children. Crowley’s personal investment in the outcome—both financially and emotionally—drove him to navigate regulatory pathways, secure funding, and pursue a therapy that the broader medical community initially viewed as unlikely to succeed. His children survived, thanks to treatment derived from research at Novazyme, and the therapy eventually became part of the standard of care for Pompe disease patients worldwide. Crowley’s leadership role at BIO reflects his deep understanding of the systemic barriers that prevent patients from accessing breakthrough treatments. He has spent years advocating for policies, regulations, and industry practices that accelerate drug development and address the gap between scientific discovery and patient access. His keynote at the Believe Ball will carry this perspective: someone who knows firsthand that innovation without scale is incomplete, and that the most important measure of scientific success is whether it reaches the patients who need it most.
The Emily Whitehead Foundation’s Mission and Philadelphia’s Medical Legacy
Emily Whitehead became the first child in the world to be successfully treated with CAR T-cell therapy when she was six years old, after conventional leukemia treatments had failed. Her treatment at the Children’s Hospital of Philadelphia marked a turning point in cancer immunotherapy, demonstrating that a patient’s own immune cells could be engineered to recognize and destroy cancer cells with remarkable precision. The success of her case launched CAR T-cell therapy into clinical practice and inspired the creation of the Emily Whitehead Foundation, an organization dedicated to advancing access to advanced cancer therapies and supporting patients navigating rare diseases and cutting-edge treatments. The choice to host the 2026 Believe Ball in Philadelphia is deliberate and symbolically rich. Philadelphia has established itself as a global hub for advanced cell and gene therapies, with world-class research institutions, patient advocacy organizations, and biopharmaceutical companies concentrated in the region. The city’s infrastructure for developing, testing, and delivering breakthrough medicines is unmatched in the United States, making it a fitting home for a gala that celebrates both patient hope and scientific possibility.
Emily Whitehead’s own story is inseparable from Philadelphia’s medical community, and the foundation leverages this connection to bring stakeholders together around shared goals. However, the work of advancing rare disease and cancer therapies faces real limitations that neither innovation nor funding alone can overcome. Clinical trials require patients willing to take extraordinary risks on unproven treatments. Manufacturing CAR T-cell therapies at scale presents technical challenges that cost tens of millions of dollars to solve. Regulatory pathways, while evolving to support innovation, still require evidence of safety and efficacy that can take years to accumulate. The Believe Ball does not ignore these constraints—instead, it brings together the people necessary to navigate them: patients who understand the urgency, scientists working on the next generation of therapies, manufacturers learning how to produce them reliably, healthcare providers figuring out how to deliver them, and industry leaders like Crowley who can shape policy and business strategy to support the entire ecosystem.
How Crowley’s Personal Journey Informs His Leadership at BIO
Crowley’s role as president and CEO of the Biotechnology Innovation Organization places him at the center of industry-wide conversations about drug pricing, patent protection, regulatory efficiency, and equitable access. These conversations are not abstract policy debates—they directly affect whether experimental therapies reach patients. Crowley speaks from lived experience: he knows what it means to be a parent desperate for a therapy that does not yet exist, willing to mortgage his future and navigate uncharted regulatory and scientific terrain in pursuit of a cure. This perspective has shaped his advocacy and his leadership philosophy. At BIO, Crowley represents the interests of biotechnology companies ranging from tiny startups pursuing single rare diseases to large pharmaceutical firms developing treatments for millions of patients. His ability to speak credibly to both the business realities and the human urgency of drug development gives him unusual influence.
When Crowley argues for regulatory reforms or IP protections, he does so as someone who understands that these policies directly determine whether the next desperate parent will have access to a cure. His keynote at the Believe Ball will likely touch on these themes: the necessity of innovation, the reality that innovation requires capital and time, and the moral imperative to build systems that get life-saving treatments to patients before it is too late. One practical tension that Crowley navigates regularly is the balance between speed and safety. Experimental therapies carry real risks. Some patients in early clinical trials of advanced therapies have experienced serious side effects, and some have died. Accelerating the path to approval must not mean abandoning the scientific rigor necessary to understand what works and what is dangerous. Crowley’s credibility rests partly on his acknowledgment of this tradeoff—he is not simply cheerleading for faster approvals, but rather advocating for smarter, more efficient development pathways that protect patient safety while minimizing unnecessary delays.
Why the Believe Ball Matters to Industry Leaders and the Broader Biotech Community
The 2026 Believe Ball is not a typical industry conference or fundraising gala. It is structured explicitly as a bridge between two groups that often operate in separate worlds: patients and families facing life-or-death medical decisions, and the scientists, manufacturers, healthcare providers, and business leaders whose work determines what treatments become available. Over 400 guests will attend, creating an environment where a patient who survived CAR T-cell therapy might sit at dinner next to the executive directing manufacturing scale-up at a biopharmaceutical company, or a caregiver might speak directly to a regulatory affairs officer about the barriers their family faced accessing an advanced therapy. For industry leaders, events like the Believe Ball serve an essential function: they restore clarity about who benefits from innovation. It is easy, when working within the technical and business constraints of drug development, to lose sight of the ultimate purpose—the patients whose lives hang in the balance.
Crowley, in particular, brings authority to this reminder because his entire career has been built on the conviction that business and science must ultimately serve patients. His keynote will likely emphasize that the most profitable and meaningful path forward for biotechnology is one that successfully translates scientific breakthroughs into treatments that are actually available, affordable, and accessible to the people who need them. The limitation of events like the Believe Ball is that they are inclusive only to a small number of people. Four hundred guests, while substantial, represents a tiny fraction of the patient population that could benefit from advanced therapies, or the hundreds of thousands of people working in biotechnology and related fields. The real work of scaling happens outside the ballroom—in manufacturing facilities, regulatory agencies, insurance companies, and hospital systems. The Believe Ball is a catalyst and a gathering point, but the translation of its message into systemic change requires the sustained commitment of those who attend, carried back into their organizations and decisions.
CAR T-Cell Therapy and the Challenge of Bringing Innovation to Scale
CAR T-cell therapy represents one of biotechnology’s most significant recent achievements, but also one of its most complicated logistical challenges. The therapy involves extracting immune cells from a patient, genetically engineering them to recognize cancer cells, expanding them to therapeutic numbers in the laboratory, and then returning them to the patient’s body. When it works, the results can be extraordinary—patients with blood cancers that had been considered fatal can achieve complete remission. When it does not work, the therapy fails or causes severe side effects that some patients have not survived. The manufacturing complexity of CAR T-cell therapies creates a fundamental bottleneck: each treatment is, in a sense, custom-made for an individual patient. This means that scaling CAR T-cell therapy requires not just scientific innovation, but innovations in manufacturing, logistics, quality control, and regulatory oversight. Companies have invested billions of dollars in building facilities capable of producing CAR T-cell therapies at scale, but these facilities remain expensive to operate and require highly specialized personnel.
A single batch failure can delay patient treatment or require starting the entire manufacturing process over. Insurance companies, hospitals, and healthcare systems have struggled to determine pricing that reflects the extraordinary complexity and personalization involved while remaining accessible to patients who need the therapy. One critical warning that Crowley and others in the biotech community frequently emphasize is the danger of assuming that medical innovation automatically becomes available to all patients who need it. History shows many examples of breakthrough therapies that remain inaccessible to large populations due to cost, geography, or systemic barriers. CAR T-cell therapy, despite its success in clinical trials, remains available in relatively limited settings and accessible primarily to patients with sophisticated healthcare coverage or the financial means to navigate complex medical systems. The Believe Ball, by bringing together industry leaders and patient advocates, attempts to make visible the gap between what is scientifically possible and what is actually available to most patients. Crowley’s role as BIO president positions him to influence how the industry responds to this gap.
The Role of Rare Disease Advocacy in Accelerating Breakthrough Treatments
The Emily Whitehead Foundation and similar patient advocacy organizations have become increasingly central to the biotech innovation ecosystem. Rare disease patient groups, in particular, have demonstrated an ability to accelerate research and development by funding studies, recruiting patients for clinical trials, and advocating for regulatory reforms that speed approval of experimental therapies. These advocacy organizations often operate with a sense of urgency that even the most committed pharmaceutical companies sometimes lack—when a disease is fatal and no treatment exists, waiting years for additional evidence can feel like an unacceptable delay.
The foundation has supported research, advocated for access to CAR T-cell therapies, and created educational programs for patients and families navigating advanced treatment options. By hosting the Believe Ball and inviting leaders like Crowley to address the gathering, the foundation signals that patient advocacy and industry leadership are not opposing forces but essential partners in the work of getting life-saving treatments to patients. Crowley’s presence and his keynote address reinforce this message: the future of biotechnology depends on sustained dialogue between those with urgent medical needs and those with the resources and expertise to meet those needs.
The September 25, 2026 Gathering and What It Represents
The 2026 Believe Ball will take place on Friday, September 25, at The Crystal Tea Room in Philadelphia’s Wanamaker Building, a historic venue that will host over 400 guests from across the advanced therapies community. The specific date and location carry practical significance—September allows time for attendees across the country and internationally to arrange travel, and the Wanamaker Building, with its architectural grandeur and central Philadelphia location, creates a setting that reflects the significance of the gathering. For attendees, the event will offer not only Crowley’s keynote address but also opportunities to hear from patients, scientists, and other industry leaders about the current state and future directions of advanced therapies.
Crowley’s address will likely center on themes that have defined his career: the intersection of personal mission and business imperative, the necessity of innovation, and the moral urgency of making life-saving treatments available to patients who need them. He will speak as someone whose children’s lives were saved by the kind of innovation that the Believe Ball celebrates, and whose professional role now involves shaping the policies and business practices that determine whether other families will have access to similar opportunities. For the patients and caregivers in attendance, his presence represents evidence that the biotechnology industry includes leaders who understand, at a profound level, why the work of developing breakthrough therapies matters.
